Test Price
3,000 AED✅ Home Collection Available
Lung Cancer Panel 2 (EGFR, ALK1, ROS1) Mutation Analysis in UAE
Executive Summary & Core Metrics
- Guaranteed Precision: 99.9% diagnostic sensitivity achieved through ISO-standard laboratory processing and orthogonal confirmation (FISH + Sanger sequencing).
- Secure Medical Courier Solid Tissue Specimen Retrieval: Archival FFPE blocks or unstained biopsy slides are collected by our accredited medical courier network under strict chain-of-custody protocols.
- Telephonic Clinical Guidance: A follow-up consultation with a specialist radiologist is provided to interpret findings and coordinate targeted therapy options within the multidisciplinary tumour board framework.
- Direct Insurance Verification: Contact us via WhatsApp at +971 54 548 8731 to confirm your outpatient oncology coverage prior to specimen submission.
Test Overview & Methodology
The Lung Cancer Panel 2 (EGFR, ALK1, ROS1) mutation analysis simultaneously detects actionable genomic alterations in non‑small cell lung carcinoma (NSCLC) using fluorescence in situ hybridisation (FISH) and Sanger sequencing. This combined approach identifies canonical exon 19 deletions and L858R point mutations in EGFR, ALK gene rearrangements, and ROS1 fusions from a single formalin‑fixed, paraffin‑embedded (FFPE) tumour specimen, enabling precision oncology decisions without the need for repeat biopsies.
| Feature | Our Panel | Closest Alternative (Single EGFR) |
|---|---|---|
| Detection Method | FISH + Sanger Sequencing (comprehensive coverage) | FISH or PCR for one gene only |
| Genes Analysed | EGFR, ALK1, ROS1 simultaneously | EGFR alone or ALK FISH only |
| Diagnostic Sensitivity | 99.9% accredited sensitivity | 85–90% may miss rare mutations |
| Turnaround Time | 5–7 working days | 7–14 days in some centres |
| Regulatory Certification | DHA‑licenced, ISO‑compliant | Varies; not guaranteed |
Physician Insight & Safety Protocols
"Interpreting an NSCLC biomarker panel requires correlation with histology, clinical stage, and prior treatment history. This test reliably identifies targetable driver mutations, but the final treatment decision must always be made within a multidisciplinary tumour board that considers overall patient performance status and co‑existing organ function."
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Medical Advisory
⚠ Important Notice: Do not discontinue or alter any prescribed oncologic therapy, tyrosine kinase inhibitor, or investigational agent based solely on these molecular results. Treatment modifications must be supervised by the managing medical oncologist.
This molecular panel is an adjunctive diagnostic tool and does not substitute for a comprehensive clinical evaluation, including imaging, histopathological review, and functional status assessment.
Exclusion Criteria & Emergency Flags
- This test requires a valid prescription from a qualified oncologist or pulmonologist. It is not intended for pre‑surgical clearance, pregnancy screening, or international travel health certificates.
- Specimens must originate from a confirmed NSCLC diagnosis; the panel is not validated for small cell lung carcinoma, mesothelioma, or benign pulmonary lesions.
- If you are experiencing acute dyspnoea, haemoptysis, or sudden neurological deterioration, proceed immediately to the nearest emergency department — do not wait for biomarker results.
- Exclusion: Not applicable for patients without explicit oncologist referral; not a substitute for urgent clinical assessment.
Patient FAQ & Clinical Guidance
1. When is this lung cancer panel clinically indicated?
This panel is indicated for adult patients with a histologically confirmed diagnosis of non‑small cell lung carcinoma (NSCLC), particularly those with adenocarcinoma histology, to identify targetable EGFR, ALK1, and ROS1 alterations before initiating first‑line tyrosine kinase inhibitor therapy. It is also recommended upon disease progression to assess acquired resistance mechanisms.
2. How is the specimen collected and what is the turnaround time?
An archived FFPE tumour tissue block or a set of unstained biopsy slides (4–6 sections, 4–5 µm thick) is retrieved via our Secure Medical Courier Solid Tissue Specimen Retrieval network. Our accredited courier collects the pathology material directly from the hospital or referring laboratory under strict chain‑of‑custody documentation. Results are reported within 5–7 working days, followed by a telephonic clinical guidance session with a specialist radiologist.
3. Does my health insurance cover this molecular panel in the UAE?
We perform direct insurance eligibility verification via WhatsApp (+971 54 548 8731) before specimen collection. Our network contracts with major UAE insurers including DHA‑regulated plans, Abu Dhabi Health Authority networks, and international private medical insurers. Coverage varies by policy; we confirm your specific outpatient oncology benefits and any prior authorisation requirements prior to proceeding.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Governance
All patient genomic data and clinical records are processed in strict compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Clinical testing safety and informed consent protocols adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability.
The laboratory operates under DHA Facility License Number 1143 and maintains ISO 9001:2015 quality management system certification (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | Lung Cancer Panel 2 (EGFR, ALK1, ROS1) Mutation Analysis |
| Price (AED) | 3,000 AED |
| Turnaround Time | 5–7 working days |
| Sample Type / Matrix | Formalin‑Fixed Paraffin‑Embedded (FFPE) Tumour Tissue Block / Archival Biopsy Slides. Secure Medical Courier Solid Tissue Specimen Retrieval — home phlebotomy is not applicable for archival tissue specimens. |
| Methodology Used | Fluorescence In Situ Hybridisation (FISH) + Sanger Sequencing |
| ICD-10-CM Code | C34.90 (Malignant neoplasm of unspecified part of unspecified bronchus or lung) |
| LOINC Code | 92815-7 (EGFR gene mutations found [Identifier] in Tissue or Cancer specimen by Sequencing) |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians